Moderna and Merck announced August 19 that a phase 3 trial of their experimental personalized mRNA cancer therapy, intismeran, in combination with Keytruda (pembrolizumab), met two key endpoints in pe...

After years of contending with steep stock drops, cash burn and political headwinds, Moderna delivered the kind of triumph biotech startups rarely enjoy twice.

Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to stoke investor excitement.